ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.750,92
0,00%
S&P 500
5.308,13
0,09%
US Dollar vs BRL
5,1039
-0,01%
Bitcoin
71.357,93
-0,13%
Brent Oil
82,26
-1,52%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Precipio Inc (PRPO)

  7. Precipio Inc (PRPO) Notícias

PRPO

Precipio (PRPO)

Precipio Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRPO
DataHoraFonteTítuloCódigoCompanhia
14/05/202417:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRPOPrecipio Inc
06/05/202418:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRPOPrecipio Inc
06/05/202418:00GlobeNewswire Inc.Precipio Secures a short-term $500K Credit FacilityNASDAQ:PRPOPrecipio Inc
25/03/202418:00GlobeNewswire Inc.Precipio Announces Year end 2023 Shareholder Update CallNASDAQ:PRPOPrecipio Inc
13/02/202412:00GlobeNewswire Inc.Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoYNASDAQ:PRPOPrecipio Inc
06/02/202412:00GlobeNewswire Inc.Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for CancerNASDAQ:PRPOPrecipio Inc
23/01/202412:00GlobeNewswire Inc.Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarterNASDAQ:PRPOPrecipio Inc
19/01/202418:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRPOPrecipio Inc
17/01/202412:30GlobeNewswire Inc.Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in JapanNASDAQ:PRPOPrecipio Inc
04/01/202418:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRPOPrecipio Inc
04/01/202418:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PRPOPrecipio Inc
02/01/202411:00GlobeNewswire Inc.Precipio Announces Christina Valauri joins the Board of DirectorsNASDAQ:PRPOPrecipio Inc
14/12/202318:30GlobeNewswire Inc.Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024NASDAQ:PRPOPrecipio Inc
16/11/202319:00GlobeNewswire Inc.Precipio Announces Q3-2023 Shareholder Update CallNASDAQ:PRPOPrecipio Inc
18/10/202310:00GlobeNewswire Inc.Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022NASDAQ:PRPOPrecipio Inc
03/10/202311:00GlobeNewswire Inc.Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023NASDAQ:PRPOPrecipio Inc
28/09/202310:00GlobeNewswire Inc.Precipio Continues to Sign New HemeScreen™ CustomersNASDAQ:PRPOPrecipio Inc
25/09/202312:00GlobeNewswire Inc.Precipio Reduces Product Revenue Result Needed for Cash Flow BreakevenNASDAQ:PRPOPrecipio Inc
13/09/202310:30GlobeNewswire Inc.Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of PlanNASDAQ:PRPOPrecipio Inc
10/08/202318:00GlobeNewswire Inc.Precipio Announces Q2-2023 Shareholder Update CallNASDAQ:PRPOPrecipio Inc
08/08/202310:00GlobeNewswire Inc.Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 PanelNASDAQ:PRPOPrecipio Inc
03/08/202310:00GlobeNewswire Inc.Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards BreakevenNASDAQ:PRPOPrecipio Inc
01/08/202310:00GlobeNewswire Inc.Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023NASDAQ:PRPOPrecipio Inc
20/07/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRPOPrecipio Inc
07/07/202317:30Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PRPOPrecipio Inc
15/06/202318:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PRPOPrecipio Inc
14/06/202310:49GlobeNewswire Inc.Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow BiopsyNASDAQ:PRPOPrecipio Inc
13/06/202310:00GlobeNewswire Inc.Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® TechnologyNASDAQ:PRPOPrecipio Inc
09/06/202317:02Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PRPOPrecipio Inc
08/06/202309:30GlobeNewswire Inc.Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:PRPOPrecipio Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRPO

Seu Histórico Recente

NASDAQ
BTTX
Better Therapeutics
TSXV
GRI
Galore Resources
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados